# Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

> **NCT02826564** · PHASE1 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT02826564
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-14
- **Primary completion:** 2018-04-02
- **Final completion:** 2019-02-18
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826564, "Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02826564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*